metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results	deaths (OS) E	progression or deaths (PFS) E	RFS/DFS E
mOC - L1 - all population metastatic/advanced OC (mOC) - 1st line (L1) mOC - L1 - all population
versus placebo plus SoC
	atezolizumab plus SoC
	IMagyn-050 (all population), 2021 Int J Gynecol Cancer 2019 Jan 10;ijgc-2018-000071. J Clin Oncol 2021 Apr 23;JCO2100306. NCT03038100	RCT	mOC - L1 - all population	atezolizumab plus paclitaxel carboplatin and bevacizumalb	placeb plus paclitaxel carboplatin and bevacizumalb	patients with stage III or stage IV epithelial ovarian, fallopian tube, or primaryperitoneal cancer with either macroscopic residual disease or who will undergo neoadjuvant chemotherapy followed by interval surgery	651 / 650	low	inconclusive
mOC - L1 - PDL1 positive metastatic/advanced OC (mOC) - 1st line (L1) mOC - L1 - PDL1 positive
versus placebo plus SoC
	atezolizumab plus SoC
	IMagyn-050 (PDL1 >1%), 2021 Int J Gynecol Cancer 2019 Jan 10;ijgc-2018-000071. J Clin Oncol 2021 Apr 23;JCO2100306. NCT03038100	RCT	mOC - L1 - PDL1 positive	atezolizumab plus paclitaxel carboplatin and bevacizumalb	placeb plus paclitaxel carboplatin and bevacizumalb	patients with stage III or stage IV epithelial ovarian, fallopian tube, or primaryperitoneal cancer with either macroscopic residual disease or who will undergo neoadjuvant therapy followed by interval surgery, PDL1 positive population	391 / 393	low	suggested
metastatic/advanced OC (mOC) - 2nd line (L2) metastatic/advanced OC (mOC) - 2nd line (L2)
versus pegylated liposomal doxorubicin
	avelumab alone
	JAVELIN ovarian 200 (A vs doxorubicin), 2021 Future Oncol 2018 Sep;14(21):2103-2113. Lancet Oncol 2021 Jun 15;S1470-2045(21)00216-3. NCT02580058	RCT	metastatic/advanced OC (mOC) - 2nd line (L2)	avelumab	Pegylated liposomal doxorubicin	Patients with platinum-resistant/refractory epithelial ovarian, fallopian tube, or peritoneal cancer, unselected for PD-L1 expression (ovarian cancer) a maximum of three previous lines for platinum-sensitive disease (most recent line containing platinum) with no previous systemic therapy for platinum-resistant disease	188 / 190	some concern	inconclusive
	avelumab plus pegylated liposomal doxorubicin
	JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 Future Oncol 2018 Sep;14(21):2103-2113. Lancet Oncol 2021 Jun 15;S1470-2045(21)00216-3. NCT02580058	RCT	metastatic/advanced OC (mOC) - 2nd line (L2)	avelumab plus PLD	Pegylated liposomal doxorubicin	Patients with platinum-resistant/refractory epithelial ovarian, fallopian tube, or peritoneal cancer, unselected for PD-L1 expression (ovarian cancer) a maximum of three previous lines for platinum-sensitive disease (most recent line containing platinum) with no previous systemic therapy for platinum-resistant disease	188 / 190	some concern	inconclusive